Advertisement

Pharma Giant Glenmark Drops Covid-19 Drug Favipiravir’s Price By 27 Per Cent

The price drop aims to make the anti-virus drug more accessible to patients across India.

Pharma Giant Glenmark Drops Covid-19 Drug Favipiravir’s Price By 27 Per Cent
SHARES

In an exchange filing on Monday, the Glenmark Pharmaceuticals Ltd said that it has reduced the price of its anti-Covid-19 drug Favipiravir to ₹ 75 per pill. The drug is sold under the brand name of 'FabiFlu' and was earlier sold for ₹103 per pill. Through this move, the pharma major has slashed the price of its much in demand drug by 27 per cent. With this price cut, Glenmark aims to make the anti-coronavirus drug more accessible to infected patients across the nation.

The filing said that the price reduction has been made possible through benefits that were gained from higher yields, as both the Active Pharmaceutical Ingredient (API) and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country. As per reports, the company has stated that it has successfully developed the API through its own in-house research team in India.

To monitor the efficiency and safety of the drug, Glenmark has also started a post-marketing surveillance study on 1,000 patients prescribed FabiFlu. The company further stated that the study is meant to be open-label, multicentered and a single-arm study. In the month of June, the Drug Control General of India gave approval of Glenmark’s favipiravir after a trial on more than 100 patients in May. 

Glenmark has also stated that they have completed the phase-3 clinical trial with their drug FabiFlu in mild to moderate COVID-19 patients in India and that the trial results are expected to be available soon. Along with this, the pharma company is also conducting another phase-3 clinical trial to test the efficiency of two anti-viral drugs, Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult coronavirus patients in the country. 


RELATED TOPICS